Medical Advocates
Aspergillosis
... again aspergillosis has different forms pulmonary aspergillosis or the Drugs
 
General Reports      
 Amphotericin B         
Amphotericin B Deoxycholate   
 Caspofungin                             
Fluconazole                               
G-CSF
Interferon Gamma
Isavuconazole
Itraconazole
M-CSF
 		 Micafungin
Omalizumab
Posaconazole 
Quinupristin 
Ravuconazole 
Rifabutin
Rec Anti-IgE Antibody
SPK-843
Voriconazole
 
 
Aspergillosis Main Page Main New/Newsworthy  Home Page 

Last Update:  April 01, 2017
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

         Journal Papers, Abstracts, and Commentaries  

 
FULL-TEXT ARTICLE
Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.
Burgel PR, Paugam A, Hubert D, Martin C.
Infect Drug Resist. 2016 Sep 20;9:229-238. Review.
 Paper

Current and future therapies for invasive aspergillosis.
Bassetti M, Pecori D, Della Siega P,  et al
Pulm Pharmacol Ther. 2014 Jun 30.
 Abstract
 

Invasive Aspergillosis: Adjunctive Combination Therapy.
Ruhil S, Balhara M, Dhankhar S,  et al
Mini Rev Med Chem. 2012 May 22.
Abstract

Efficacy of combination antifungal therapy of intraperitoneal micafungin with aerosolized
liposomal amphotericin B in murine invasive pulmonary aspergillosis.
Takazono T, Izumikawa K, Mihara T,et al
Antimicrob Agents Chemother. 2009 Jun 1
 Abstract

Invasive pulmonary aspergillosis after liver transplantation: rapid and complete response
to combined and sequential antifungal therapy.
Can MF, Yagci G, Gorenek L, et al 
Surg Infect (Larchmt). 2008 Feb;9(1):99-104
 Abstract

Multi-azole resistance in Aspergillus fumigatus.
Howard SJ, Webster I, Moore CB  
Int J Antimicrob Agents. 2006 Nov;28(5):450-3.
 Abstract
 
Aspergillosis in systemic diseases treated with steroids and/or immunosuppressive drugs:
report of 9 cases and literature review.
Stankovic K, Seve P, Hot A, Magy-Bertrand N, et al
Rev Med Interne. 2006 Nov;27(11):813-827.
Abstract
 
Aspergillosis in systemic diseases treated with steroids and/or immunosuppressive drugs:
report of 9 cases and literature review
Stankovic K, Seve P, Hot A, Magy N, et al
Rev Med Interne. 2006 Aug 24;
Abstract
 
Is combination antifungal therapy for invasive aspergillosis a necessity in
hematopoietic stem-cell transplant recipients?
Leather HL, Wingard JR.
Curr Opin Infect Dis. 2006 Aug;19(4):371-9.
 Abstract
 
Combination and sequential antifungal therapy for invasive aspergillosis: review of
published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
Steinbach WJ, Stevens DA, Denning DW. 
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S188-224.
 Abstract

Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.
Bennett JE, Powers J, de Pauw B, et al.
Clin Infect Dis 2003 Apr 15;36(Suppl 3):S113-6
 Abstract
Amphotericin B
 

         Journal Papers, Abstracts and Commentaries  

 
Amphotericin B+ and voriconazole+echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A, Mouton JW, Verweij PE,  et al
Antimicrob Agents Chemother. 2013 Jul 15
 Abstract

Aerosolized liposomal amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
Kamalaporn H, Leung K, Nagel M,  et al
Pediatr Pulmonol. 2013 Jul 10.
 Abstract

Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.
Monforte V, Ussetti P, Gavaldà J, et al
J Heart Lung Transplant. 2010 Jan
Abstract

Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B.
Solé A.
 Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S161-5.
 Abstract
 
Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic
Murine Model of
Invasive Pulmonary Aspergillosis.
Lewis RE, Albert ND, Kontoyiannis DP.
Antimicrob Agents Chemother. 2008 Aug 25.
 Abstract
 
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis
during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ, Cornelissen JJ, Slobbe L 
Clin Infect Dis. 2008 May 1;46(9):1401-8.
 Abstract
 
Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive
pulmonary aspergillosis.
Greene RE, Mauskopf J, Roberts CS, et al  
Am J Health Syst Pharm. 2007 Dec 15;64(24):2561-8.
Abstract
 
Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose
for patients with invasive aspergillosis: AmBiLoad trial.
Lass-Flörl C.
Expert Rev Anti Infect Ther. 2007 Dec;5(6):929-32.
 Abstract
 
Treatment of Invasive Pulmonary Aspergillosis in Neutropenic Patients by Additional
Bronchoscopic Amphotericin B Instillation.
Winkler J, Müller U, Nenoff P, et al
Respiration. 2007 Jul 6;
Abstract
 
Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive
aspergillosis.
Wingard JR, Herbrecht R, Mauskopf J, et al
Transpl Infect Dis. 2007 Jul 1;
 Abstract
 
Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment
of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal
mitochondrial disorder.
Castagnola E, Moresco L, Cappelli B, et al
J Chemother. 2007 Jun;19(3):339-42.
 Abstract
 
Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis
and other filamentous fungal infections in immunocompromised hosts: a pooled
analysis.
Cordonnier C, Bresnik M, Ebrahimi R.
Mycoses. 2007 May;50(3):205-9.
Abstract
 
Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
Schwartz S, Ruhnke M, Ribaud P, et al
Mycoses. 2007 May;50(3):196-200.
 Abstract
 
Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections.
Mohammad RA, Klein KC   
Ann Pharmacother. 2006 Dec;40(12):2148-54.
 Abstract
 
FULL-TEXT PDF ARTICLE
Invasive aspergillosis: Is treatment with "inexpensive" amphotericin B cost saving if "expensive"
voriconazole is only used on demand?
Garbino J, Schnetzler G, Roberts C, et al 
Swiss Med Wkly. 2006 Sep 30;136(39-40):624-630.
 Paper
 
Antifungal interactions within the triple combination of amphotericin B, caspofungin
and voriconazole against Aspergillus species.
O'shaughnessy EM, Meletiadis J, Stergiopoulou T, et al  
J Antimicrob Chemother. 2006 Oct 27
Abstract

Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe
invasive pulmonary aspergillosis.
Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA
Antimicrob Agents Chemother. 2006 May;50(5):1852-4.
 Abstract

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma
concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP, Tam VH, Chi J,
Antimicrob Agents Chemother. 2006 Feb;50(2):469-73.
Abstract
 
FULL-TEXT ARTICLE
A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin
B and INF-gamma.
Mamishi S, Zomorodian K, Saadat F, et al 
Ann Clin Microbiol Antimicrob. 2005 Mar 3;4(1):4
 Paper

Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec
(Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Clemons KV, Stevens DA.  
Antimicrob Agents Chemother. 2004 Mar;48(3):1047-50.
 Abstract
 
FULL TEXT ARTICLE
An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive
aspergillosis in Canada.
Rotstein C, Laverdière M, Marciniak A, Ali F.
Can J Infect Dis Med Microbiol. 2004 Sep;15(5):277-84.
Paper


Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model
of disseminated aspergillosis.
Takemoto K, Yamamoto Y, Ueda Y,
J Antimicrob Chemother. 2004 Jan 16
 Abstract

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and
micafungin.
Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK.
J Antimicrob Chemother. 2003 Oct;52(4):656-62
 Abstract

Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following
treatment with amphotericin B.
Paterson PJ, Seaton S, Prentice HG, et al 
J Antimicrob Chemother. 2003 Sep 30
Abstract
 
Efficacy of amphotericin B or itraconazole in a murine model of centralnervous system
Aspergillus infection.
Chiller TM, Sobel RA, Luque JC, et al.
Antimicrob Agents Chemother 2003 Feb;47(2):813-5
 Abstract

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R,  Denning DW,
Patterson TF, et al. N Engl J Med 2002 Aug 8;347(6):408-15
Abstract

Prophylactic administration of liposomal amphotericin B is superior to treatment in a
murine model of invasive aspergillosis after hematopoietic cell transplantation.
BitMansour A, Brown JM
Infect Dis 2002 Jul 1;186(1):134-7
 Abstract

Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by
combination of AmBisome with Fungizone as assessed by several parameters of
antifungal response.
Becker MJ, De Marie S, Fens MH, et al.
J Antimicrob Chemother 2002 May;49(5):813-20
 Abstract

  
Amphotericin B Deoxycholate
 

    Journal Papers, Abstracts, and Commentaries  

 
Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for
prevention of invasive fungal infections following lung transplantation: a retrospective
study.
Lowry CM, Marty FM, Vargas SO, et al
Transpl Infect Dis. 2007 Jun;9(2):121-5.
 Abstract

Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model
of disseminated aspergillosis.
Takemoto K, Yamamoto Y, Ueda Y,
J Antimicrob Chemother. 2004 Jan 16
 Abstract
   
  Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by
combination of AmBisome with Fungizone as assessed by several parameters of
antifungal response.
Becker MJ, De Marie S, Fens MH, et al.
J Antimicrob Chemother 2002 May;49(5):813-20
 Abstract
Caspofungin
 

    Journal Papers, Abstracts, and Commentaries  

 
Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry.
 Egerer G, Reichert D, Pletz MW, et al
Eur J Med Res. 2012 Apr 17;17(1):7
 Abstract

 Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials.
Yuan X, Wang R, Bai CQ,  et al
Pharmazie. 2012 Apr;67(4):267-73.
 Abstract

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic
stem cell transplant patients: an European Organisation for Research and |Treatment of Cancer study.
Herbrecht R, Maertens J, Baila L,  et al
Bone Marrow Transplant. 2010 Jan 11.
Abstract

Invasive aspergillosis caused by Aspergillus terreus in a living donor liver transplant recipient successfully treated by caspofungin.
Walter J, Sobottka I, Rogiers X,  et al
Mycoses. 2009 Dec 30.
 Abstract

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in
haematological patients.
Viscoli C, Herbrecht R, Akan H, et al  
J Antimicrob Chemother. 2009 Oct 19.
 Abstract

Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment:
laboratory characteristics and implication for susceptibility testing.
Arendrup MC, Garcia-Effron G, Buzina W, et al
Antimicrob Agents Chemother. 2008 Dec 22.
Abstract
 
Caspofungin for treatment of invasive aspergillus infections.
Heinz WJ, Einsele H.
 Mycoses. 2008;51 Suppl 1:47-57.
 Abstract
 
Caspofungin Modulates Inflammatory Responses to Aspergillus fumigatus through Stage-Specific
Effects on Fungal beta-GlucanExposure.
Hohl TM, Feldmesser M, Perlin DS, Pamer EG.
J Infect Dis. 2008 May 23.
 Abstract
 
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and
micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.
Lewis RE, Albert ND, Kontoyiannis DP.
J Antimicrob Chemother. 2008 May;61(5):1140-4
 Abstract
 
Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole.
Chirch L, Roche P, Fuhrer J.
Ear Nose Throat J. 2008 Jan;87(1):30-3.
 Abstract
 
Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic
organ transplantation.
Groetzner J, Kaczmarek I, Wittwer T, et al
J Heart Lung Transplant. 2008 Jan;27(1):1-6.
 Abstract
 
Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant
recipients treated with caspofungin.
Madureira A, Bergeron A, Lacroix C, et al
Int J Antimicrob Agents. 2007 Oct 26
Abstract
 
Disseminated Invasive Aspergillosis with Cerebral Involvement Successfully Treated with
Caspofungin and Voriconazole.
Gubler C, Wildi SM, Imhof A, et al 
Infection. 2007 Aug 25;
 Abstract
 
Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory
support: a case report.
Eschertzhuber S, Velik-Salchner C, Hoermann C, et al 
Transpl Infect Dis. 2007 Jul 1;
 Abstract
 
Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
Izumikawa K, Ohtsu Y, Kawabata M, et al
Med Mycol. 2007 May;45(3):273-8
 Abstract
 
Antifungal interactions within the triple combination of amphotericin B, caspofungin
and voriconazole against Aspergillus species.
O'shaughnessy EM, Meletiadis J, Stergiopoulou T, et al  
J Antimicrob Chemother. 2006 Oct 27
Abstract
 
A case of pulmonary aspergillosis with lack of response to caspofungin.
Ruchel R, Perske C, Glass B, Basecke J.
Rev Iberoam Micol. 2006 Jun;23(2):94-6.
Abstract
 
Caspofungin: an advanced treatment approach for suspected or confirmed
invasive aspergillosis.
Maertens J.
Int J Antimicrob Agents. 2006 Jun;27(6):457-67.
Abstract
 
Caspofungin: an advanced treatment approach for suspected or confirmed invasive
aspergillosis.
Maertens J.  
Int J Antimicrob Agents. 2006 May 13;
Abstract
 
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in
neutropenic patients.
Betts R, Glasmacher A, Maertens J, et al
Cancer. 2005 Dec 13;
Abstract

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin
 compassionate use study.
Kartsonis NA, Saah AJ, Joy Lipka C, et al  
J Infect. 2005 Apr;50(3):196-205.
Abstract
 
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis:
evidence of concentration-dependent activity.
Wiederhold NP, Kontoyiannis DP, Chi J, et al   
J Infect Dis. 2004 Oct 15;190(8):1464-71.
Abstract
 
Caspofungin--a new therapeutic option for oropharyngeal candidiasis.
Garbino J. 
Clin Microbiol Infect. 2004 Mar;10(3):187-9
 Abstract

Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis:
a case report.
Taccone FS, Marechal R, Meuleman N, Aoun M.
Support Care Cancer. 2003 Sep 6
 Abstract
 
Caspofungin: first approved agent in a new class of antifungals.
Johnson MD, Perfect JR.
Expert Opin Pharmacother 2003 May;4(5):807-23
 Abstract
 		  
Caspofungin: the first representative of a new antifungal class.
Letscher-Bru V, Herbrecht R.  
J Antimicrob Chemother 2003 Mar;51(3):513-21
 Abstract

Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA, Gelone SP.
Ann Pharmacother 2003 Jan;37(1):90-8
 Abstract

 Caspofungin: pharmacology, safety and therapeutic potential in superficial and
invasive f
ungal infections.
Groll AH, Walsh TJ.
Expert Opin Investig Drugs 2001 Aug;10(8):1545-58
 Abstract

  
Fluconazole
 

   Journal Papers, Abstracts, and Commentaries     

  Fungal infections in marrow transplant recipients under antifungal prophylaxis
with fluconazole.
Oliveira JS, Kerbauy FR, Colombo AL, et al.
Braz J Med Biol Res 2002 Jul;35(7):789-98
 Abstract		  
G-CSF
 

    Journal Papers, Abstracts, and Commentaries

  Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during
long-term bone marrow suppression in hypoplastic leukemia
Nishii K, Mitani H, Miyashita H, Hoshino N, et al.
Rinsho Ketsueki 2002 Mar;43(3):189-93
 Abstract
Interferon Gamma
 

    Journal Papers, Abstracts, and Commentaries

 
Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients
 with pulmonary aspergillosis.
Bandera A, Trabattoni D, Ferrario G, et al
Infection. 2008 Aug;36(4):368-73.
 Abstract

Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis.
Kelleher P, Goodsall A, Mulgirigama A, et al
Eur Respir J. 2006 Jun;27(6):1307-10.
 Abstract
Itraconazole
 

    Journal Papers, Abstracts, and Commentaries     

 
FULL-TEXT ARTICLE
Azole resistance in Aspergillus fumigatus associated with treatment failure.
Howard SJ, Cerar D, Anderson MJ, et al.
Emerg Infect Dis 2009 Jul
 Paper

A case of allergic bronchopulmonary aspergillosis that itraconazole showed a definite effect
temporarily.
Isobe Z, Suga T, Hamaguchi S, Hara K, et al 
Arerugi. 2007 Nov;56(11):1390-6.
 Abstract
 
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary
aspergillosis.
Alvarez CA, Wiederhold NP, McConville JT. et al
J Infect. 2007 Mar 12;
Abstract
 
Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis:
A randomized controlled trial.
Wark PA, Hensley MJ, Saltos N,et al.
J Allergy Clin Immunol 2003 May;111(5):952-957
 Abstract
 
Efficacy of amphotericin B or itraconazole in a murine model of central nervous system
Aspergillus infection.
Chiller TM, Sobel RA, Luque JC, et al.
Antimicrob Agents Chemother 2003 Feb;47(2):813-5
 Abstract
 
Intravenous Itraconazole followed by Oral Itraconazole for the Treatment of
Amphotericin-B-Refractory Invasive Pulmonary Aspergillosis.
Caillot D
Acta Haematol 2003;109(3):111-8
 Abstract
 
Itraconazole--perspectives for the management of invasive aspergillosis.
Groll AH.
Mycoses 2002;45 Suppl 3:48-55
 Abstract
 
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a
murine model of acute invasive pulmonary
aspergillosis.
Lewis RE, Prince RA, Chi J, Kontoyiannis DP.
Antimicrob Agents Chemother 2002 Oct;46(10):3208-14
 Abstract
 
Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic
fibrosis.
Skov M, Hoiby N, Koch C.
 Allergy 2002 Aug;57(8):723-8
Abstract

Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole
and budesonide.
Skov M, Main KM, Sillesen IB, et al
Eur Respir J 2002 Jul;20(1):127-33
 Abstract

Profound adrenal suppression secondary to treatment with low dose inhaled steroids
and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.
Parmar JS, Howell T, Kelly J, Bilton D.
 Thorax 2002 Aug;57(8):749-50
 Abstract

Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic
fibrosis.
Skov M, Hoiby N, Koch C.
 Allergy 2002 Aug;57(8):723-8
 Abstract
 
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those
of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and
other filamentous fungi: report from  SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA, Messer SA, Hollis RJ, et al.
Antimicrob Agents Chemother 2002 Apr;46(4):1032-7
 Abstract

 
Isavuconazole
 
    Journal Papers, Abstracts, and Commentaries     
 
 

FULL-TEXT ARTICLE
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trial in Adults and Target Attainment in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai A, Kovanda L, Kowalski D,  et al
Antimicrob Agents Chemother. 2016 Jul 5.
 Paper

Isavuconazonium sulfate: A New Agent for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis.
Kovanda LL, Maher R, Hope WW.
Expert Rev Clin Pharmacol. 2016 May 10
 Abstract
M-CSF
 
    Journal Papers, Abstracts, and Commentaries     
 
  Successful treatment of invasive pulmonary aspergillosis with G-CSF and
M-CSF during long-term bone marrow suppression in hypoplastic leukemia
Nishii K, Mitani H, Miyashita H, Hoshino N, et al.
Rinsho Ketsueki 2002 Mar;43(3):189-93
 Abstract
Micafungin
 
    Journal Papers, Abstracts, and Commentaries     
 
 
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and
micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.
Lewis RE, Albert ND, Kontoyiannis DP.
J Antimicrob Chemother. 2008 May;61(5):1140-4
 Abstract
 
Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with
micafungin.
Ouchi H, Fujita M, Ikegame S, et al
J Infect Chemother. 2007 Aug;13(4):258-62.
 Abstract
 
FULL-TEXT PDF ARTICLE
Effective blood concentration of micafungin for pulmonary aspergillosis.
Shimoeda S, Ohta S, Kobayashi H, et al 
Biol Pharm Bull. 2006 Sep;29(9):1886-91
 Abstract
 
Micafungin therapy for a case of chronic necrotizing pulmonary aspergillosis
Sugino Y, Fujii M, Kato M, Yagi A, Kawabata A.
Nihon Kokyuki Gakkai Zasshi. 2006 Jun;44(6):458-63
 Abstract

Micafungin (FK463), alone or in combination with other systemic antifungal agents,
for the treatment of acute invasive aspergillosis. 
Denning DW, Marr KA, Lau WM, et al
J Infect. 2006 May 5;
 Abstract
 
Micafungin (FK463), alone or in combination with other systemic antifungal agents,
for the treatment of acute invasive aspergillosis.
Denning DW, Marr KA, Lau WM, et al
J Infect. 2006 May 5;
 Abstract
 

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B
and micafungin.
Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK.
J Antimicrob Chemother. 2003 Oct;52(4):656-62
 Abstract

Efficacy of micafungin alone or in combination against systemic murine aspergillosis.
Luque JC, Clemons KV, Stevens DA.
Antimicrob Agents Chemother 2003 Apr;47(4):1452-5
 Abstract
Omalizumab
 
    Journal Papers, Abstracts, and Commentaries     
 
  Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases.
Aydın Ö, Sözener ZÇ, Soyyiğit Ş,
Allergy Asthma Proc. 2015 Nov;36(6):493-500.
Abstract

Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.
Collins J, Devos G, Hudes G, Rosenstreich D.
 J Asthma Allergy. 2012;5:65-70.
 Abstract

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and
cystic fibrosis.
Zirbes JM, Milla CE. et al 
Pediatr Pulmonol. 2008 Apr 23
 Abstract
Posaconazole
 
    Journal Papers, Abstracts, and Commentaries     
 
 
Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.
Crombag MR, Huisman C, Kemper EM,  et al
Ther Drug Monit. 2012 Jun;34(3):320-5.
 Abstract

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with
hematologic malignancies: posaconazole compared with high-dose lipid formulations of
amphotericin B alone or in combination with caspofungin.
Raad II, Hanna HA, Boktour M, et al  
Leukemia. 2007 Dec 20
Abstract
 
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or
intolerant of conventional therapy: an externally controlled trial.
Walsh TJ, Raad I, Patterson TF, et al  
Clin Infect Dis. 2007 Jan 1;44(1):2-12.
 Abstract

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those
of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and
other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA, Messer SA, Hollis RJ, et al.
Antimicrob Agents Chemother 2002 Apr;46(4):1032-7
 Abstract
Quinupristin
 
    Journal Papers, Abstracts, and Commentaries     
 
  Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia
and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to
multiple treatments for Hodgkin's lymphoma.
Muto H, Kaneko S, Machino T, et al  J Infect Chemother. 2006 Dec;12(6):391-5.
 Abstract
Ravuconazole
 
    Journal Papers, Abstracts, and Commentaries     
 
  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of
itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other
filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA, Messer SA, Hollis RJ, et al.
Antimicrob Agents Chemother 2002 Apr;46(4):1032-7
 Abstract
Rifabutin
 
    Journal Papers, Abstracts, and Commentaries     
 
  Effect of a 150 mg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease.
Moon SM, Jhun BW, Lee H,et al    
J Infect Chemother. 2017 Mar 8.
 Abstract

Effect of a 150 mg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease.
Moon SM, Jhun BW, Lee H, et al  
J Infect Chemother. 2017 Mar 8
 Abstract
Recombinant Anti-IgE Antibody
 
    Journal Papers, Abstracts, and Commentaries     
 
  Successful treatment of allergic bronchopulmonary aspergillosis with recombinant
anti-IgE antibody.
van der Ent CK, Hoekstra H, Rijkers GT.  
Thorax. 2007 Mar;62(3):276-7.
 Abstract
SPK-843
 
    Journal Papers, Abstracts, and Commentaries     
 
  Efficacy of SPK-843, a Novel Polyene Antifungal in Murine Pulmonary Aspergillosis in Comparison
with Amphotericin B,
AmBisome(R) and Micafungin.Kakeya H, Miyazaki Y, Senda H 
Antimicrob Agents Chemother. 2008 Feb 25
Abstract
Voriconazole
 

         Journal Papers, Abstracts, and Commentaries     

 
Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.
Kim SB, Cho SY, Lee DG, et al 
Med Mycol. 2016 Aug 25.
Abstract

Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient.
 Ambrosioni J, Coll S, Manzardo C, et al
J Antimicrob Chemother. 2016 Jan 10
 Abstract

A Case Report of Mass-Forming Aspergillus Tracheobronchitis Successfully Treated with Voriconazole.
Kim DS, Jeong JS, Kim SR,  et al
Medicine (Baltimore). 2015 Aug;94(34):e1434.
 Abstract

Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Becker A, Sifaoui F, Gagneux M,  et al
Int J STD AIDS. 2014 Sep 1
 Abstract

Amphotericin B+ and voriconazole+echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A, Mouton JW, Verweij PE,  et al
Antimicrob Agents Chemother. 2013 Jul 15
 Abstract

FULL-TEXT ARTICLE
 Orbital aspergillosis: voriconazole - the new standard treatment?
Ohlstein DH, Hooten C, Perez J,  et al
Case Report Ophthalmol. 2012 Jan;3(1):46-53.
 Paper

Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients.
Luong ML, Hosseini-Moghaddam SM, et al
Am J Transplant. 2012 Apr 5.
Abstract

FULL-TEXT ARTICLE
Poststernotomy aspergillosis: successful treatment with voriconazole, surgical debridement and vacuum-
assisted closure therapy.
Siciliano RF, Waisberg DR, Samano MN, et al
Clinics (Sao Paulo). 2012;67(3):297-9.
Paper

FULL-TEXT PDF ARTICLE
Neuroaspergillosis in an immunocompetent patient successfully treated with
voriconazole and a corticosteroid.
Hiraga A, Uzawa A, Shibuya M, et al 
Intern Med. 2009;48(14):1225-9
 Paper

Antifungal Therapy of Aspergillus Invasive Otitis Externa: Efficacy of Voriconazole and Review.
Parize P, Chandesris MO, Lanternier F, Poirée S, et al
 Antimicrob Agents Chemother. 2008 Dec 22.
Abstract
 

Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole
in patients with chronic respiratory disease
Hagiwara E, Sekine A, Sato T, Baba T,
 Nihon Kokyuki Gakkai Zasshi. 2008 Nov;46
 Abstract
 
Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A, Hoffman J, Sheth A.
Ann Pharmacother. 2008 Dec;42(12):1859-64
 Abstract
 
A case of orbital apex syndrome caused by invasive aspergillosis successfully treated during the diagnostic
procedure by the use of voriconazole
Sugai A, Oyake M, Umeda M, Umeda Y, Fujita N.
Rinsho Shinkeigaku. 2008 Oct;48(10):746-9.
 Abstract
 
Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole.
Chirch L, Roche P, Fuhrer J.
Ear Nose Throat J. 2008 Jan;87(1):30-3.
 Abstract
 
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy
and safety outcomes.
Pascual A, Calandra T, Bolay S, et al  
Clin Infect Dis. 2008 Jan 15;46(2):201-11.
 Abstract
 
Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive
pulmonary aspergillosis.
Greene RE, Mauskopf J, Roberts CS, et al  
Am J Health Syst Pharm. 2007 Dec 15;64(24):2561-8.
Abstract
 
Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully
treated with voriconazole.
Erwin GE, Fitzgerald JE. 
J Asthma. 2007 Dec;44(10):891-5.
Abstract
 
Invasive tracheal aspergillosis treated successfully with voriconazole: clinical report and
review of the literature.
Warman M, Lahav J, Feldberg E, Halperin D.
Ann Otol Rhinol Laryngol. 2007 Oct;116(10):713-6.
Abstract
 
FULL-TEXT ARTICLE
Response of central nervous system aspergillosis to voriconazole.
Balasubramaniam P, Madakira PB, Ninan A, Swaminathan A.
Neurol India. 2007 Jul-Aug;55(3):301-3.
Paper
 
Disseminated Invasive Aspergillosis with Cerebral Involvement Successfully Treated with
Caspofungin and Voriconazole.
Gubler C, Wildi SM, Imhof A, et al 
Infection. 2007 Aug 25;
 Abstract
 
Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients.
Veroux M, Corona D, Gagliano M, et al 
Transplant Proc. 2007 Jul-Aug;39(6):1838-40.
 Abstract
 
Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive
aspergillosis.
Wingard JR, Herbrecht R, Mauskopf J, et al
Transpl Infect Dis. 2007 Jul 1;
 Abstract
 
Treatment of chronic pulmonary aspergillosis by voriconazole in non-immunocompromised
patients.
Camuset J, Nunes H, Dombret MC, et al 
Chest. 2007 Mar 30
 Abstract
 
Antifungal interactions within the triple combination of amphotericin B, caspofungin
and voriconazole against Aspergillus species.
O'shaughnessy EM, Meletiadis J, Stergiopoulou T, et al  
J Antimicrob Chemother. 2006 Oct 27
Abstract
 
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated
young woman.
Elter T, Sieniawski M, Gossmann A, et al Int
J Antimicrob Agents. 2006 Sep;28(3):262-5.
 Abstract
 
Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H, Dupont B, Lode H, Denning DW.
Am J Med. 2006 Jun;119(6):527.
Abstract
 
Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated
with voriconazole.
Wandroo F, Stableforth P, Hasan Y. et al  
Clin Lab Haematol. 2006 Apr;28(2):130-3.
Abstract
 
Economic evaluation of voriconazole versus conventional amphotericin B in the treatment
of invasive aspergillosis in Germany.
Jansen JP, Kern WV, Cornely OA, et al  
Value Health. 2006 Jan-Feb;9(1):12-23.
Abstract
 
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in
solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N, Limaye AP, Forrest G, et al  
Transplantation. 2006 Feb 15;81(3):320-6.
 Abstract
 
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jorgensen K, Gotzsche P, Johansen H.
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004707.
 Abstract
 
The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary
aspergillosis.
Jain LR, Denning DW.
J Infect. 2006 Jan 19;
 Abstract
 
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jorgensen K, Gotzsche P, Johansen H.
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004707.
Abstract
 
Economic evaluation of voriconazole compared with conventional amphotericin B for the
primary treatment of aspergillosis in immunocompromised patients.
Wenzel R, Del Favero A, Kibbler C, et aL   
J Antimicrob Chemother. 2005 Mar;55(3):352-61
 Abstract
 
Successful treatment of brain aspergillosis with voriconazole.
Tattevin P, Bruneel F, Lellouche F, et al.
Clin Microbiol Infect. 2004 Oct;10(10):928-31.
 Abstract
 
FULL TEXT ARTICLE
An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive
aspergillosis in Canada.
Rotstein C, Laverdière M, Marciniak A, Ali F.
Can J Infect Dis Med Microbiol. 2004 Sep;15(5):277-84.
Paper
 
Histological examination of an eye with endogenous Aspergillus endophthalmitis treated
with oral voriconazole: a case report
Aliyeva SE, Ullmann AJ, Kottler UB, et al  
Graefes Arch Clin Exp Ophthalmol. 2004 Mar 30
Abstract

Two Cases of Cerebral Aspergillosis Successfully Treated with Voriconazole.
De Lastours V, Lefort A, Zappa M, et al.  
Eur J Clin Microbiol Infect Dis 2003 May 10;
Abstract
 
Voriconazole: a new triazole antifungal agent.
Pearson MM, Rogers PD, Cleary JD, Chapman SW.
Ann Pharmacother 2003 Mar;37(3):420-32
 Abstract

Voriconazole: in the treatment of invasive aspergillosis.
Muijsers RB, Goa KL, Scott LJ. et al.
Drugs 2002;62(18):2655-64
 Abstract

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R,  Denning DW,
Patterson TF, et al. N Engl J Med 2002 Aug 8;347(6):408-15
Abstract

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those
of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and
other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA, Messer SA, Hollis RJ, et al.
Antimicrob Agents Chemother 2002 Apr;46(4):1032-7
 Abstract
 
 

Aspergillosis Main Page Main New/Newsworthy  Home Page 

Aspergillosis Drugs